Still betting on Nvidia? Our AI picked this stock instead; it’s up 96%+ THIS MONTH
LONDON - Haleon plc (LSE/NYSE:HLN), a global consumer health company, announced the results of its 2025 Annual General Meeting (AGM) today, with all resolutions passed by shareholders. The meeting saw the passage of both ordinary and special resolutions as determined by poll votes.
The company reported overwhelming support for the receipt of the Annual Report & Accounts, with 99.99% of votes in favor. Similarly, the Directors’ Remuneration Report was approved with 98.73% of the votes cast. Shareholders also declared a final dividend, with nearly unanimous consent at 99.99%.
Key board members, including Sir Dave Lewis (JO:LEWJ) and Brian McNamara, were re-elected with substantial majority votes. New electoral candidates Dawn Allen, Nancy Avila, Bláthnaid Bergin, and Alan Stewart were also elected, each receiving over 99% approval.
The reappointment of KPMG as the company’s auditor and the authorization for the Audit & Risk Committee to set the auditor’s remuneration were approved with 99.95% and 99.97% of the votes, respectively.
In terms of special resolutions, the company received authorization to disapply pre-emption rights, with 95.88% of votes for the general authority and 93.58% for additional authority. The authorization of a 14-day notice period for general meetings was approved with 92.46% of the votes. Furthermore, the resolution to allow the company to purchase its own shares passed with 99.92% approval.
The AGM’s decisions reflect shareholder confidence in Haleon’s governance and strategic direction. These results are expected to be submitted to the Financial Conduct Authority and made available for public inspection.
The voting turnout represented 83.48% to 83.56% of the issued share capital, indicating strong shareholder engagement. Votes withheld, which are not considered legal votes, were also reported for each resolution.
Haleon is known for its portfolio of consumer health products, including brands like Advil, Centrum, and Sensodyne. The company has a stated purpose of delivering better everyday health with humanity, emphasizing trusted science and innovation.
This summary is based on a press release statement and reflects the outcomes of Haleon’s AGM held today.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.